WO2002052275A2 - Verfahren zur bestimmung der blutzellhämostase - Google Patents
Verfahren zur bestimmung der blutzellhämostase Download PDFInfo
- Publication number
- WO2002052275A2 WO2002052275A2 PCT/DE2001/004815 DE0104815W WO02052275A2 WO 2002052275 A2 WO2002052275 A2 WO 2002052275A2 DE 0104815 W DE0104815 W DE 0104815W WO 02052275 A2 WO02052275 A2 WO 02052275A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- factor
- whole blood
- blood sample
- step lit
- added
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/7454—Tissue factor (tissue thromboplastin, Factor III)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96444—Factor X (3.4.21.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96447—Factor VII (3.4.21.21)
Definitions
- the invention relates to a method for determining blood cell hemostasis, in particular blood coagulation triggered by the intravascular tissue factor, and a kit for carrying out the method.
- the object of the invention is to eliminate the disadvantages of the prior art.
- a simple and reliable method for determining blood coagulation in whole blood is to be specified.
- Another object is to provide a kit for performing the method.
- factor V ⁇ Ia (i) is added. This is factor Vlla, which is derivatized in the active center: factor V ⁇ Ia (i) binds with a higher affinity than factor Vlla. It does not activate coagulation and inhibits fibrin formation.
- the method according to the invention has the particular advantage that it can be carried out simply and inexpensively. No plasma from the whole blood sample is required to carry out the method be won. Another advantage is that the coagulation triggered by TF can be measured specifically without the need for complex processes, for example processes to be carried out under flow conditions.
- the method is based on the surprising finding that after stimulation of whole blood with collagen, platelet-leukocyte complexes quickly present TF on their surface.
- the functionally active TF of the blood obviously plays a decisive role as a starter of blood coagulation and for the formation of arterial and venous thrombosis.
- 3a and b show the triggering of functional TF activities in complexes from isolated leukocytes and platelets.
- Fig. 1 The results shown in Fig. 1 were obtained by incubating whole blood for various time periods at 37 ° C without (unfilled symbols) and with collagen (12 ⁇ g / ml, filled symbols).
- the leukocytes were fixed and incubated with FITC-labeled isotype-matching control antibodies and with FITC-labeled anti-TF antibodies.
- the association of the antibodies with the leukocytes was analyzed using flow cytometry.
- Fig. 1 represent the time course of the appearance of monocyte- (Fig. La) and neutrophil-associated TF (Fig. Lb).
- the presentation of the TF associated with the leukocytes shows a maximum within 5-10 minutes after stimulation with collagen.
- Fig. 2 show the rate of fibrin production and clot formation (r and k values). These values were determined by means of thrombography of the whole blood (at room temperature).
- Fig. 2a control test;
- Fig. 3a shows the activation of factor X by isolated monocytes (10 5 , prepared by micro-bead technique; white columns) and isolated neutrophils (10 6 , also prepared by micro-bead technique, gray columns) for 5 minutes were incubated at 37 ° C with or without collagen (12 ⁇ g / ml). If indicated, isolated platelets (10 7 ) were added to the leukocyte suspensions in question.
- the picture Factor Xa was detected using the chromogenic substrate S2222, as essentially described in Surprenant, YM and Zuckerman, SH (1989) Thro b. Res. 53, pages 339-346.
- factor Xa The activation of factor X by isolated neutrophils and monocytes remains unchanged after the addition of collagen. In suspensions of untreated platelets with isolated leukocytes, the formation of factor Xa is as low as in the presence of leukocytes alone. However, if the platelet-leukocyte suspension is activated by collagen, the factor Xa formation is significantly increased (FIG. 3a).
- a whole blood sample is taken in a conventional manner.
- the whole blood sample is then stabilized by adding a coagulant substance.
- the anticoagulant substance can be citrate; a concentration of e.g. 0.38% (volume percent) set.
- At least one component of the extracellular matrix is added to the stabilized whole blood sample, e.g. Collagen in a concentration of 8 to 15 ⁇ g / ml, preferably 12 ⁇ g / ml.
- the factor V ⁇ Ia (i) is also added, preferably in a concentration of about 1 ⁇ M.
- an inhibitor that excludes contact activation is added to the whole blood sample at any time prior to the addition of factor V ⁇ Ia (i), e.g. the com trypsin inhibitor in a concentration of 10 to 100 ⁇ g / ml, preferably 50 ⁇ g / ml.
- the sample can be recalcified, preferably using a CaCl solution with a concentration of 100 mM.
- the blood coagulation activity can then be determined using a conventional method, for example thromlastography, ball coagulometry or the crochet method.
- Matrix components are preferably added to the recalculated whole blood.
- the matrix components are highly specific activators that trigger coagulation in whole blood.
- factor V ⁇ Ia (i) the proportion of fibrin formation induced by TF in the total fibrin production mediated by collagen can be determined.
- recombinant TF can also be added to the whole blood sample. This makes it possible to record the effects of vascular wall and blood cell TF.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10064689.1 | 2000-12-22 | ||
DE10064689A DE10064689B4 (de) | 2000-12-22 | 2000-12-22 | Verfahren zur Bestimmung der Blutzellhämostase |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002052275A2 true WO2002052275A2 (de) | 2002-07-04 |
WO2002052275A3 WO2002052275A3 (de) | 2002-08-08 |
Family
ID=7668752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2001/004815 WO2002052275A2 (de) | 2000-12-22 | 2001-12-19 | Verfahren zur bestimmung der blutzellhämostase |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE10064689B4 (de) |
WO (1) | WO2002052275A2 (de) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472850A (en) * | 1991-04-10 | 1995-12-05 | Oklahoma Medical Research Foundation | Quantitative clotting assay for activated factor VII |
WO1999003498A1 (en) * | 1997-07-18 | 1999-01-28 | Novo Nordisk A/S | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY |
-
2000
- 2000-12-22 DE DE10064689A patent/DE10064689B4/de not_active Expired - Fee Related
-
2001
- 2001-12-19 WO PCT/DE2001/004815 patent/WO2002052275A2/de not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472850A (en) * | 1991-04-10 | 1995-12-05 | Oklahoma Medical Research Foundation | Quantitative clotting assay for activated factor VII |
WO1999003498A1 (en) * | 1997-07-18 | 1999-01-28 | Novo Nordisk A/S | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY |
Non-Patent Citations (4)
Title |
---|
GIESEN P L A ET AL: "BLOOD-BORNE TISSUE FACTOR: ANOTHER VIEW OF THROMBOSIS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, Bd. 96, M{rz 1999 (1999-03), Seiten 2311-2315, XP002939775 ISSN: 0027-8424 in der Anmeldung erw{hnt * |
JOHNSON DANIEL J D ET AL: "Crystallization and preliminary X-ray analysis of active site-inhibited human coagulation factor VIIa (des-Gla)." JOURNAL OF STRUCTURAL BIOLOGY, Bd. 125, Nr. 1, M{rz 1999 (1999-03), Seiten 90-93, XP001074734 ISSN: 1047-8477 * |
RAUCH U ET AL: "Circulating tissue factor and thrombosis." CURRENT OPINION IN HEMATOLOGY. UNITED STATES SEP 2000, Bd. 7, Nr. 5, September 2000 (2000-09), Seiten 273-277, XP008003987 ISSN: 1065-6251 in der Anmeldung erw{hnt * |
VALENTIN SANNE ET AL: "Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: A comparison between tissue factor pathway inhibitor and inactive factor Vlla." THROMBOSIS AND HAEMOSTASIS, Bd. 74, Nr. 6, 1995, Seiten 1478-1485, XP008003991 ISSN: 0340-6245 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002052275A3 (de) | 2002-08-08 |
DE10064689A1 (de) | 2002-07-04 |
DE10064689B4 (de) | 2004-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0661383B1 (de) | Verfahren zur Bestimmung der Thrombozytenaggregation | |
EP2484776B1 (de) | Heparin-insensitives Verfahren zur Bestimmung von direkten Gerinnungsfaktorinhibitoren | |
EP1561116A2 (de) | Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen | |
EP0537490A2 (de) | Funktioneller Test und Reagenz zur Bestimmung von Fibrinogen | |
DE10309368A1 (de) | Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase | |
DE4427785A1 (de) | Verfahren zum Nachweis von Störungen des Protein C/Protein S-Systems | |
EP0656424B1 (de) | Test zur Bestimmung der Empfindlichkeit gegenüber aktiviertem Protein C | |
WO2002052275A2 (de) | Verfahren zur bestimmung der blutzellhämostase | |
EP0972203B1 (de) | REAGENS ZUR BESTIMMUNG DER aPTT | |
EP1973929B1 (de) | Antikoagulation von humanem blut ex vivo | |
DE4439756C2 (de) | Kalibrator zur Verwendung in Testverfahren zum Nachweis eines defekten Gerinnungsfaktors V | |
EP0570354B1 (de) | Verfahren zur Bestimmung von Fibrinogen | |
DE3783840T2 (de) | Verfahren zur bestimmung von plasma-protein und testsatz dafuer. | |
DE19538716A1 (de) | Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa) | |
EP0825443B1 (de) | Verfahren zur Quantifizierung von Glykosaminoglykanen in Antithrombin III-haltigen Lösungen | |
WO2006089697A1 (de) | Verfahren zur bestimmung der gesamtgerinnungsaktivität einer blut- oder plasmaprobe | |
EP0255651A2 (de) | Mittel zur Therapie faktor VIII-resistenter Hämophilie A und Verfahren zu seiner Herstellung | |
WO2000050904A1 (de) | Testkit zur analytik der faktor-viii-spaltenden protease | |
DE3014076A1 (de) | Neue heparin-fraktionen mit erhoehter antikoagulans-wirkung | |
EP0445626A2 (de) | Funktioneller Test zur Bestimmung der Protein S-AktivitÀ¤t | |
DE4418635A1 (de) | Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen | |
EP1784649A1 (de) | Polypeptidmarker zur diagnose von arteriosklerose | |
DE19506263A1 (de) | Verfahren zum spezifischen Nachweis eines Gerinnungsfaktors V mit einer erhöhten Stabilität gegenüber aktiviertem Protein C im aktivierten Zustand | |
DE19731684A1 (de) | Thrombin-Reagenz | |
AT402074B (de) | Reagens zur bestimmung der aptt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |